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Key summary points
Aim To describe the prevalence of probable sarcopenia in a sample of older adults and to investigate (1) the SARC-F tool 
and (2) clinical risk factors in the identification of probable sarcopenia.
Findings The prevalence of probable sarcopenia at age 69 was 19%, and a SARC-F score of ≥ 1 had a reasonable balance 
of sensitivity (65%) and specificity (72%) for probable sarcopenia. Three clinical risk factors were independently associated 
with probable sarcopenia: polypharmacy, lower body osteoarthritis and physical inactivity.
Message Those with any positive responses to the questions in the SARC-F tool, a history of polypharmacy, lower body 
osteoarthritis or physical inactivity should be prioritised for the assessment of muscle strength.
Abstract
Purpose The European Working Group on Sarcopenia in Older People 2 (EWGSOP2) consensus definition introduced the 
concept of probable sarcopenia as a basis on which to begin treatment. Our aims were to describe the prevalence of probable 
sarcopenia in older adults and to investigate the utility of (1) the SARC-F tool and (2) clinical risk factors for the identifica-
tion of those likely to have probable sarcopenia.
Methods We used data from the 1946 British birth cohort at age 69, with 1686 participants included in the analyses. We 
used the EWGSOP2 cut points for weak grip strength and slow chair rise time, with the presence of one or both indicat-
ing probable sarcopenia. We examined the sensitivity and specificity of the SARC-F tool for probable sarcopenia. We also 
examined associations between clinical risk factors and probable sarcopenia.
Results The prevalence of probable sarcopenia was 19%. A SARC-F score of ≥ 4 had low sensitivity (15%) and high speci-
ficity (99%) for probable sarcopenia, whereas a score of ≥ 1 had higher sensitivity (65%) and reasonable specificity (72%). 
Three clinical risk factors were independently associated with probable sarcopenia: polypharmacy [OR 2.7 (95% CI 1.7, 
4.2)], lower body osteoarthritis [OR 1.8 (95% CI 1.3, 2.6)] and physical inactivity [OR of 2.1 (95% CI 1.5, 2.8)].
Conclusion We have shown that EWGSOP2 probable sarcopenia is common in community-dwelling adults in early old age. 
Those with any positive responses to the questions in the SARC-F tool, a history of polypharmacy, lower body osteoarthritis 
or physical inactivity should be prioritised for the assessment of muscle strength.
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Introduction
Sarcopenia, the accelerated loss of muscle strength and 
mass, is linked to a range of adverse outcomes including 
disability [1, 2] and is amenable to interventions including 
resistance exercise training and nutritional supplementa-
tion [3, 4]. The recent European Working Group on Sar-
copenia in Older People 2 (EWGSOP2) consensus defini-
tion facilitates the clinical identification of sarcopenia by 
incorporating the SARC-F tool as a screening measure and 
by introducing the concept of probable sarcopenia (PS) 
[5]. PS is the presence of low muscle strength based on 
poor performance in the grip strength test, the chair rise 
test or both. It is a basis on which to begin intervention, 
including in situations where it is not possible to assess 
muscle mass.
The sensitivity and specificity of the SARC-F tool to 
screen for sarcopenia defined according to the original 
EWGSOP consensus definition have been summarised in 
a systematic review and meta-analysis of seven studies [6]. 
It was found to have low sensitivity [0.21, 95% confidence 
interval (CI) 0.13–0.31], but high specificity (0.90, 95% 
CI 0.83–0.94). A subsequent study using a Turkish sample 
found similar values [7]. The latter study also found that the 
SARC-F tool had only a moderate sensitivity for detecting 
poor performance in the grip strength and chair rise tests, 
although using different cut points to those now recom-
mended by EWGSOP2. A recent study of 306 community-
dwelling participants at mean age 75 years found a sensitiv-
ity of 0.47 and specificity of 0.87 for EWGSOP2-confirmed 
sarcopenia using SARC-F [8]. As far as we are aware, there 
has been little exploration of the sensitivity and specific-
ity of SARC-F to screen specifically for PS as defined by 
EWGSOP2.
The alternative approach recommended for screening 
for PS in the EWGSOP2 definition is to use clinical suspi-
cion. Previous studies (using the earlier EWGSOP defini-
tion of sarcopenia) suggest that risk factors include being 
underweight, a history of routine/manual occupation, lower 
physical activity levels and the presence of long-term condi-
tions [9–11]. We are not aware of studies that have exam-
ined risk factors for EWGSOP2 PS, and hence, it is less 
clear who to prioritise for the assessment of muscle strength. 
Using data from a British birth cohort study, the Medical 
Research Council National Survey of Health and Develop-
ment (NSHD) [12, 13], our aims were firstly to describe the 
prevalence of PS in a sample of older adults and secondly to 
investigate the utility of (1) the SARC-F tool and (2) clini-
cal risk factors in the identification of those most likely to 
benefit from the assessment of muscle strength.
Methods
Participants
We used data from the NSHD, a socially stratified sample 
of 5362 singleton births in 1 week of March 1946 in main-
land Britain that have been followed up 24 times across life, 
most recently in 2015 (at age 69) [12, 13]. At age 69, study 
members still alive and with a known current address in 
mainland Britain (n = 2698) were invited to have a home 
visit; 2149 (79.7%) completed a visit, 55 (2.0%) completed 
a postal questionnaire instead and 494 (18.3%) did not par-
ticipate [13]. Of the original cohort, 1026 (19.1%) had died, 
578 (10.8%) were living abroad, 22 (0.4%) asked for their 
participation to be restricted to postal contacts, 621 (11.6%) 
had previously withdrawn from the study, and 417 (7.8%) 
had been lost to follow-up.
Ethical approval for this most recent follow-up was 
obtained from the NRES Queen Square Research Ethics 
Committee (14/LO/1073) and the Scotland A REC (14/
SS/1009). Written, informed consent was obtained from 
study members for each component of the data collection.
Assessment of muscle strength
Grip strength was assessed in the seated position using a 
Jamar Plus + Digital Hand dynamometer. Participants com-
pleted two trials in both hands, with the maximum value 
used in analyses. In the chair rise test, participants were 
asked to go from a seated position to standing with straight 
legs and back, and then sit down again, 10 times as fast as 
possible. We used a conversion equation to estimate the time 
taken to perform five chair rises, as described further in sta-
tistical analyses, below and in the supplementary methods.
We used the EWGSOP2 cut points for PS: grip strength 
of less than 27 kg in men and 16 kg in women, and/or time 
to complete five chair rises of greater than 15 s [5]. We con-
sidered those unable to do either test for health reasons to 
have PS for the purpose of analyses [14].
Assessment of SARC‑F and clinical risk factors
The SARC-F questionnaire has five components, compris-
ing: difficulty in walking across a room, number of falls in 
the last year, strength (difficulty with lifting or carrying a 
10 lb weight), difficulty with chair or bed transfers and dif-
ficulty with climbing stairs. Each is scored 0–2 in order of 
increasing difficulty and a score of 4 or more suggesting the 
presence of sarcopenia [15]. The difficulty in walking and 
fall components were asked in the NSHD as per the SARC-
F questionnaire. The original strength component was not 
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asked. We therefore used difficulty carrying shopping as 1 
point and difficulty in holding a full kettle as 2 points. The 
chair and bed transfer component was assessed, but only in 
terms of difficulty with each of these two activities and not 
the degree to which this was present. We therefore scored 
difficulty with either chair or bed transfers as 1 point and 
difficulty with both as 2 points. Finally, difficulty with stair 
climbing was scored as 2 points for those unable to climb 
stairs, as well as those who reported that most or all of the 
time they needed to hold on, stop for a rest or go sideways 
or one step at a time. Those reporting less severe difficulty 
with stair climbing were scored as 1 point.
We chose a range of potential risk factors for PS. Body 
mass index (BMI) was calculated from height and weight 
measured using standard protocols and was grouped into 
below 25, 25–30 and above 30 kg/m2. Number of prescribed 
medications was categorised into 0, 1, 2–4, 5–8 (polyphar-
macy) and 9 + (excessive polypharmacy). Multimorbidity 
was based on the count of the following long-term condi-
tions: asthma, cancer, diabetes, epilepsy, depression, high 
blood pressure, lung disease, transient ischaemic attack 
(TIA), eye disease, kidney disease, osteoarthritis, osteopo-
rosis, Parkinson’s disease, rheumatoid arthritis and vascular 
disease (defined as having had angina, a heart attack, aortic 
aneurysm, raised cholesterol, deep vein thrombosis, atrial 
fibrillation, narrowing of arteries or pulmonary embolism). 
The count was divided into three categories: 0, 1 and 2 + 
conditions. Lower limb osteoarthritis, of particular interest 
given its association with poor performance in the chair rise 
test [16], was considered as a separate risk factor.
Lifestyle factors included smoking status (classified 
as never, ex-smoker or current), the frequency of current 
alcohol intake (with five categories from never to four or 
more times a week), regular fruit and vegetable consump-
tion (daily or most days of the week) and participation in 
physical activity (sports or vigorous leisure activities in the 
last 4 weeks). Finally, occupation class at age 53 was cat-
egorised using the Registrar General’s Social Classification 
into three groups: I or II (high); IIINM or IIIM (medium); 
IV or V (low).
Statistical analyses
To estimate the time taken to complete five chair rises based 
on the observed values for 10 rises assessed in NSHD, we 
used data from the second wave of the English Longitudinal 
Study of Ageing [17, 18]. Full details are provided in the 
supplementary methods section. In summary, a subset of 
participants of similar age to the present study performed 
both five and 10 chair rise tests as part of the same assess-
ment, allowing us to produce a linear regression equation to 
estimate the time taken for five chair rises as used in EWG-
SOP2 [19].
We restricted our analytical sample to those with com-
plete data on PS, SARC-F and risk factors. We calculated the 
sensitivity and specificity of different SARC-F cut points of 
for the identification of PS. We used multivariable logistic 
regression to examine independent risk factors for PS. We 
also repeated the analysis using Poisson regression, given 
the PS was not a rare (< 10%) outcome in this study [20]. 
The results were unchanged when we did this. We also 
repeated the logistic regression model with SARC-F posi-
tive participants excluded, in order to model the situation 
where clinical suspicion was being applied to those who 
were negative on SARC-F. We performed all analyses using 
Stata version 14.0 [21].
Results
Characteristics of the sample
A total of 1686 participants (51% female) aged 69–70 had 
complete data on PS, SARC-F score and clinical risk factors. 
As shown in the first column of Table 1, the majority were 
in the overweight range (with a mean BMI of 28.0 kg/m2), 
were taking between two and four prescribed medications 
and had none or one of the long-term conditions that were 
used to derive a measure of multimorbidity.
Muscle strength
Fourteen participants (< 1%) were unable to do the grip 
strength test due to health reasons and were assumed to have 
low muscle strength in later analyses. Mean (SD) measured 
grip strength was 40.5 (8.4) kg and 24.5 (5.8) kg in men and 
women, respectively.
Sixty-seven participants (4%) were unable to do the 
chair rise test due to health reasons and were assumed to 
have low muscle strength. A further 25 participants could 
only do between one and nine chair rises. Those who did 
fewer than five rises, five rises taking longer than 15 s or 
between six and nine rises with a time equivalent to per-
forming five rises in greater than 15 s were also assumed 
to have low muscle strength. The median (IQR) time to 
complete five chair rises (calculated from the time taken 
to perform 10 rises, as described in the Supplementary 
Methods section) was 10.9 (9.2, 12.7) s, with no sex dif-
ference observed.
In total, 74 (4%) participants were unable to do one or 
both muscle strength tests due to health reasons. Compared 
to those who completed both tests, those who did not were 
more likely to have: a BMI in the obese category (47% com-
pared to 28%, P = 0.001), lower body osteoarthritis (35% 
compared to 15%, P < 0.001) and two or more long-term 
conditions (46% compared to 29%, P = 0.002).
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Prevalence of probable sarcopenia
Probable sarcopenia, defined as weak grip strength, slow 
chair rise time, or both, was present in 328 (19%) partici-
pants. Weak grip strength was present in 118 (7%) partici-
pants, including 14 who were unable to complete the test due 
to health reasons. Slow chair rise time was present in 259 
(15%) participants, including 67 who were unable to com-
plete the test due to health reasons. There was only limited 
overlap between weak grip strength and slow chair rise time, 
with 48 participants, or 15% of those with PS, having both 
(as shown in Fig. 1).
Table 1  Characteristics of sample
Characteristic Whole sample (N = 1686) Probable sarcopenia 
(N = 328)
No prob-
able sarcopenia 
(N = 1358)
Sex
 Male 824 (48.9%) 147 (44.8%) 677 (49.9%)
 Female 862 (51.1%) 181 (55.2%) 681 (50.1%)
BMI
  < 25 490 (29.1%) 71 (21.6%) 419 (30.9%)
 25–30 702 (41.6%) 120 (36.6%) 582 (42.9%)
  > 30 494 (29.3%) 137 (41.8%) 357 (26.3%)
Medications
 No medications 358 (21.2%) 40 (12.2%) 318 (23.4%)
 Monopharmacy 278 (16.5%) 39 (11.9%) 239 (17.6%)
 2–4 medications 698 (41.4%) 117 (35.7%) 581 (42.8%)
 Polypharmacy (5–8 medications) 289 (17.1%) 100 (30.5%) 189 (13.9%)
 Excessive polypharmacy (9 + medications) 63 (3.7%) 32 (9.8%) 31 (2.3%)
Long-term conditions
 None 596 (35.3%) 76 (23.2%) 520 (38.3%)
 1 584 (34.6%) 108 (32.9%) 476 (35.1%)
 2 or more 506 (30%) 144 (43.9%) 362 (26.7%)
Lower body osteoarthritis
 No 1418 (84.1%) 236 (72%) 1182 (87%)
 Yes 268 (15.9%) 92 (28%) 176 (13%)
Occupation class
 IV or V (low) 200 (11.9%) 41 (12.5%) 159 (11.7%)
 III (medium) 655 (38.8%) 145 (44.2%) 510 (37.6%)
 I or II (high) 831 (49.3%) 142 (43.3%) 689 (50.7%)
Smoker status
 Current smoker 131 (7.8%) 33 (10.1%) 98 (7.2%)
 Ex-smoker 1039 (61.6%) 209 (63.7%) 830 (61.1%)
 Never smoker 516 (30.6%) 86 (26.2%) 430 (31.7%)
Alcohol intake
 Never, but have drunk alcohol in the past 159 (9.4%) 44 (13.4%) 115 (8.5%)
 Monthly or less 275 (16.3%) 70 (21.3%) 205 (15.1%)
 Two to four times per month 300 (17.8%) 54 (16.5%) 246 (18.1%)
 Two to three times per week 436 (25.9%) 66 (20.1%) 370 (27.2%)
 Four or more times a week 516 (30.6%) 94 (28.7%) 422 (31.1%)
Fruit and vegetable consumption
 Infrequent 584 (34.6%) 135 (41.2%) 449 (33.1%)
 Daily or most days 1102 (65.4%) 193 (58.8%) 909 (66.9%)
Physical activity
 Inactive 954 (56.6%) 245 (74.7%) 709 (52.2%)
 Active 732 (43.4%) 83 (25.3%) 649 (47.8%)
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The identification of probable sarcopenia
The SARC‑F tool
The prevalence of any difficulty varied across the five com-
ponents of the SARC-F tool: strength (7%), assistance walk-
ing (2%), transfer from a chair or bed (5%), climbing stairs 
(17%) and falls (20%). A positive (greater than or equal to 
four) SARC-F score was present in only 60 (4%) participants. 
A positive score was more likely in those with PS compared 
to those without (15% compared to 1%, P < 0.001). The sen-
sitivity of a positive SARC-F score for PS was low at 15% 
with a specificity of 99%. However, a SARC-F cut point of 
one or above gave higher sensitivity (65%) and maintained 
reasonable specificity (72%), as shown in Fig. 2.
Clinical risk factors
As shown in Table 1, PS was more common in women 
and those with obesity, polypharmacy or excessive poly-
pharmacy, two or more long-term conditions, lower body 
osteoarthritis, current or previous smoking, no or infrequent 
alcohol consumption, low or medium occupational class, 
infrequent consumption of fruit and vegetables, and physi-
cal inactivity. All but sex and smoking history reached sta-
tistical significance (P < 0.05) in univariable analyses. We 
also examined the characteristics of those with weak grip 
strength and slow chair rise time separately, as shown in 
Table 1 in the supplementary results section. We saw an 
overall similar pattern of characteristics for those with prob-
able sarcopenia (that is poor performance in either or both 
of the two tests), although those with slow chair rise time 
appeared to have an even greater proportion of those with 
obesity and physical inactivity than those with weak grip 
strength. In supplementary results Table 1, we also examined 
the characteristics of those with both weak grip strength and 
slow chair rise time. This small group (n = 49) appeared to 
have a greater proportion of female participants and lower 
body osteoarthritis, compared to those with weak grip 
strength or slow chair rise time alone.
In a multivariable logistic regression model, number of 
medications, lower body osteoarthritis and physical inactiv-
ity continued to have a statistically significant association 
with PS, as shown in Table 2. These factors were indepen-
dently associated with an approximate doubling of the odds 
of PS: polypharmacy (including excessive polypharmacy) 
compared to no medications had an OR (odds ratio) of 2.7 
[95% CI (confidence interval) 1.7, 4.2]; lower body osteo-
arthritis had an OR of 1.8 (95% CI 1.3, 2.6); and physical 
inactivity had an OR of 2.1 (95% CI 1.5, 2.8). These asso-
ciations were unchanged when the model was repeated with 
SARC-F positive participants excluded (results not shown).
Fig. 1  Overlap between differ-
ent tests of muscle strength
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Discussion
We investigated the prevalence and identification of PS 
based on the EWGSOP2 definition in community-dwelling 
adults aged 69 participating in a British birth cohort study. 
We found a prevalence of 19% or approximately one in five 
participants. In terms of the components of PS, we found a 
higher prevalence of slow chair rise time (15%) compared to 
weak grip strength (7%). The SARC-F tool with a cut point 
of four or above, proposed for sarcopenia case finding, had 
high specificity (99%), but low sensitivity (15%), for PS. By 
comparison, a SARC-F cut point of one or above increased 
sensitivity (65%) whilst maintaining reasonable specificity 
(72%). Clinical risk factors which independently predicted 
the presence of PS were polypharmacy (five or more medi-
cations), lower body osteoarthritis and physical inactivity.
Few other studies have examined the prevalence of PS 
according to the EWGSOP2 definition. Kim and Won [22] 
reported a prevalence of 24% at mean age 76 using data from 
the Korean Frailty and Ageing Cohort Study; their findings 
and the present study highlight that in community-dwelling 
older people, there is a substantial proportion of individ-
uals who would be classified as having PS and therefore 
require further assessment. In the original EWGSOP defini-
tion, the next step would be the assessment of muscle mass 
[23], although relevant imaging such as dual-energy X-ray 
absorptiometry may not always be feasible [24]. Under the 
EWGSOP2 definition, PS is now a basis on which to assess 
potential causes and begin treatment, even if measurement 
of muscle mass is not possible.
We recently found a prevalence of PS defined using weak 
grip strength in UK Biobank participants aged 60–70 of 8% 
[25], which is similar to the prevalence of weak grip strength 
in the present study (7%). In the present study, we saw lim-
ited agreement between weak grip strength and slow chair 
rise time, with only 15% of those with PS having poor per-
formance on both tests. Further research to examine whether 
this limited agreement is also seen in other studies would be 
helpful. If confirmed, this would suggest that carrying out 
both tests in a clinical setting to assess for PS is warranted. 
This will require more time and carry the risk of older peo-
ple not being able to complete both tests, especially the chair 
rise test [26]. However, there is evidence that inability to 
complete such tests is itself a marker or poor health [14] and 
therefore an important finding.
In terms of identification of those with PS, we found 
that a SARC-F cut point of four or more (as recommended 
in the EWGSOP2 definition) was uncommon in a commu-
nity-dwelling sample at age 69, with a low sensitivity and 
high specificity for PS. A cut point of one or more had 
higher sensitivity whilst maintaining reasonable specific-
ity. Difficulty with climbing stairs and falls in the last year 
were the most common SARC-F components reported by 
participants. The presence of either of these in a patient’s 
Fig. 2  Prevalence of each 
SARC-F score and correspond-
ing sensitivity and specificity 
for probable sarcopenia. The 
bars (left-hand Y axis) show 
the prevalence of each SARC-F 
score within the sample. The 
lines (right-hand Y axis) show 
the sensitivity and specificity of 
using each SARC-F score as a 
cut point for the identification 
of PS
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history could therefore act as a flag to needing assessment 
of PS.
The low to moderate sensitivity and high specificity 
of SARC-F as a screening tool for sarcopenia has been 
described previously [6, 8]. It has been suggested that the 
addition of calf circumference [27], age and BMI [28] may 
improve the diagnostic accuracy of the SARC-F tool for 
EWGSOP2 sarcopenia. SARC-F has also been shown to 
have higher sensitivity for EWGSOP2 sarcopenia in older 
patients with hip fracture [29], perhaps due to the higher 
prevalence of sarcopenia in this group (37%) compared to 
that typically seen in community-dwelling samples.
We also examined which clinical risk factors could be 
used to identify individuals with PS who require further 
assessment, equivalent to the concept of clinical suspicion 
described in the EWGSOP2 definition. Most factors tested 
were associated with PS, but those remaining independent 
in a multivariable analysis were polypharmacy, lower body 
osteoarthritis and physical inactivity. The first two of these 
can be assessed from a patient’s medical record, and the 
third can readily be assessed in a patient’s history. The next 
step would be to undertake a validation of these factors in a 
different sample including a wider age range.
We used data from a sample in early old age, and this may 
limit the generalisability of our findings. However, there is 
growing interest in the identification of sarcopenia in midlife 
and early old age, especially in the setting of patients with 
long-term conditions [25]. We also used a different question 
Table 2  Multivariable model 
of risk factors for probable 
sarcopenia
N = 1686 in the model shown
CI confidence interval
Risk factor Association between probable sarcopenia and 
risk factor shown
Odds ratio 95% CI P
BMI category 0.071
  < 25 Reference
 25–30 1.02 0.73–1.44
  > 30 1.41 0.99–2.01
Number of medications < 0.001
  No medications Reference
  Monopharmacy 1.08 0.66–1.76
  2–4 medications 1.22 0.82–1.84
  Polypharmacy (5–8 medications) 2.40 1.54–3.79
  Excessive polypharmacy (9 + medications) 4.42 2.31–8.49
Long-term conditions 0.225
  0 Reference
  1 1.25 0.89–1.76
  2 + 1.37 0.95–1.99
Smoker status 0.638
  Never smoker Reference
  Current smoker 1.27 0.76–2.08
  Ex-smoker 1.10 0.81–1.48
Alcohol consumption 0.275
  Never, but have drunk alcohol in the past Reference
  Monthly or less 1.01 0.63–1.63
  Two to four times per month 0.77 0.47–1.26
  Two to three times per week 0.67 0.42–1.08
  4 or more times a week 0.82 0.52–1.30
Occupational class 0.360
  I or II (high) Reference
  IV or V (low) 0.81 0.52–1.23
  III (medium) 1.09 0.82–1.45
Lower body osteoarthritis 1.89 1.35–2.65 < 0.001
Infrequent consumption of fruit and vegetables 1.10 0.83–1.44 0.510
Physical inactivity 2.06 1.55–2.77 < 0.001
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to assess self-reported strength than the one in the SARC-
F tool (see “Methods” section), although given that most 
participants had an overall score of zero or one, this change 
would have been unlikely to cause a substantial reduction in 
the prevalence of participants who were SARC-F positive (a 
score of greater than or equal to four points).
In conclusion, we have shown that PS according to the 
EWGSOP2 definition is common in community-dwelling 
adults in early old age particularly if characterised by the 
presence of low grip strength or slow chair rise time. Our 
findings suggest that in this group, those with any positive 
responses to the questions in the SARC-F tool, a history of 
polypharmacy, lower body osteoarthritis or physical inac-
tivity should be prioritised for the assessment of muscle 
strength. Future work should include the investigation of 
these relationships in clinical settings and at older ages.
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